Marker Therapeutics MRKR
NASDAQ MRKR
$1.05 -0.02 (-1.87%)
At close: Oct 1, 2026 · 4:00 PM EDT

Marker Therapeutics (MRKR) Convertible Debt (2011 - 2014)

Updated

Marker Therapeutics (MRKR) posted Convertible Debt of $52,942 for Q4 2014.

Analysis

Marker Therapeutics (MRKR) Convertible Debt (2011 - 2014) Analysis & Trends

  • The Q4 2014 figure stands as the highest quarterly Convertible Debt since Q3 2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Marker Therapeutics 17.87 Mn -42.04 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 52,942.00
Sep 30, 2011 568,127.00
Jun 30, 2011 504,469.00
API Access

Marker Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=MRKR&period=max&api_key=YOUR_API_KEY